Search results
Results from the WOW.Com Content Network
For example, discontinuation of paroxetine in mice leads to anxiety-like behavior, together with a rebound over-activation of 5-HT neurons. [28] One problem is that many animal studies use fluoxetine as the study drug, despite it being not very commonly associated with withdrawal in human patients.
Stopping imipramine (Tofranil), paroxetine (Paxil or Seroxat), and venlafaxine (Effexor)/ desvenlafaxine (Pristiq) was associated with a higher risk of severe symptoms compared to other ...
Antidepressant discontinuation syndrome, also called antidepressant withdrawal syndrome, is a condition that can occur following the interruption, reduction, or discontinuation of antidepressant medication. [187] The symptoms may include flu-like symptoms, trouble sleeping, nausea, poor balance, sensory changes, and anxiety.
Paroxetine, sold under the brand name Paxil among others, is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. [7] It is used to treat major depressive disorder, obsessive-compulsive disorder, panic disorder, social anxiety disorder, post-traumatic stress disorder, generalized anxiety disorder, and premenstrual dysphoric disorder. [7]
Online, people claim they get brain zaps after stopping use of drugs like Lexapro (escitalopram), Cymbalta (duloxetine), and Paxil (paroxetine), but they can happen when you stop taking any type ...
Paroxetine may produce discontinuation-related symptoms at a greater rate than other SSRIs, though qualitatively similar effects have been reported for all SSRIs. [175] [176] Discontinuation effects appear to be less for fluoxetine, perhaps owing to its long half-life and the natural tapering effect associated with its slow clearance from the ...
Paroxetine (Paxil, Pexeva) Sertraline (Zoloft) As an SSRI antidepressant, escitalopram is commonly prescribed to treat depression. The FDA also approves it for the treatment of generalized anxiety ...
Where risks or harms is the reason for withdrawal, this will usually have been prompted by unexpected adverse effects that were not detected during Phase III clinical trials, i.e. they were only made apparent from postmarketing surveillance data collected from the wider community over longer periods of time.